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Background: Psychosocial dysfunction is one of schizophrenia’s core features, often leading to a deprecation of
independent living and significant failure to maintain a competent quality of life. Cognitive and occupational
performance as well as psychosocial functioning is moreover recognized as determinants of treatment response.
Therefore, the elaboration of measures regarding social performance besides scales that assess psychopathology is
essential. The Personal and Social Performance (PSP) scale has been found to be as much valid as reliable for
assessing social functioning in the acute and stable stage of schizophrenia. The aim of this study was to estimate
the correlation between the PSP and Positive and Negative Syndrome Scale (PANSS) (convergent validity) in
patients with schizophrenia during routine clinical practice.
Methods: A longitudinal study with a six-month follow-up is presented. Correlation between the PSP scale and the
Positive and Negative Syndrome Scale (PANSS) was conducted in a Greek sample of 2010 patients with
schizophrenia in outpatient setting in two successive visits. PANSS and PSP scales were used for the assessment of
psychopathological symptoms and social and personal functioning.
Results: The PSP subscales scores were well correlated with each other with Spearman correlation coefficients (r)
ranging from 0.56 to 0.76 on both visits in three out of the four main areas, whereas in the category of “disturbing
and aggressive behavior” the correlations were lower but still significant. Furthermore, total PSP score showed high
association to PANSS total score in the first (r = −0.59) as well as in the second visit (r = −0.50). Regression analysis
showed that one point decrease of PANSS’s total score is associated with a 0.42 points increase on the PSP scale.
PSP and PANSS scales exhibited high convergent validity.
Conclusions: The PSP could provide additional valuable information in the assessment of schizophrenia related
social functioning and treatment response.
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Schizophrenia can lead to a considerable psychosocial
dysfunction [1] and can influence significantly patients’
quality of life, resulting in the need for assistance in
meeting basic living needs [2,3]. Severe impairment in
social functioning is listed in DSM-IV criteria for diag-
nosis (Social and occupational dysfunction criterion),
covering three large domains of work/academic, inter-
personal relations and self care while it is being present
even if illness is in remission often predating the onset
of the disorder [4].
It is presumed that patients with schizophrenia either
failed to reach essential psychosocial competence or they
failed to maintain it after extended periods of social isola-
tion and hospitalization [2,3]. Nowadays cognitive and oc-
cupational performance as well as psychosocial functioning
is being recognized as determinants of treatment response
[5]. Social dysfunction has been most correlated with the
presence of negative symptoms [6-10] whereas the direct
correlation of general psychopathology and psychosocial
dysfunction [11-13] remains controversial [14].
However, the assessment of personal and social func-
tioning remains an area of controversy and uncertainty
[5,15] and scales used for assessing social functioning
often overlap clinical psychopathology [10], while this
devastating clinical, social and economic effect as well as
the introduction of new medical, psychological and social
strategies in therapeutics in recent years, requires a new
approach of the current evaluation of schizophrenia’s fea-
tures not only according to psychopathology but also for
the patients’ quality of life and social functioning [16].
The Personal and Social Performance scale (PSP)
evolved on the basis of the social functioning component
of the DSM-IV Social and Occupational functioning
Assessment Scale (SOFAS) as an effort to assess social
functioning in schizophrenia and it is being proposed as
an improvement over the Global Assessment Functioning
(GAF) scale and SOFAS [17]. PSP is a hundred-item scale,
divided in 10 similar intervals. The score is based on the
assessment of a patient’s performance in four categories;
socially useful activities, personal and social relationships,
self-care, disturbing and aggressive behavior [17]. It has
proved to be a reliable, quick measure of personal and
social functioning of patients with psychiatric disorders
displaying several advantages compared to other evaluation
tools, such as including clear operational instructions
and specific areas to be rated and not incorporating
psychopathological aspects [17].
PSP has been used successfully on patients with schizo-
phrenia in the acute [18,19] and stable stage [17,20] re-
vealing high reliability and validity.
In three clinical studies of Paliperidone, regression
analysis showed that the PSP scale may detect changes
in the total score of PANSS [21-23]. According to theanalysis, a 20% improvement on PANSS corresponds
to a 9.14 –point improvement on the PSP scale. In a
recent meta-analysis, in which 3 studies on Paliperidone
were included as well as a non-invasive cross-sectional
study, the PSP scale is recommended as a useful tool of
future research and the necessity for the examination of
psychometric characteristics of the PSP scale in different
stages of the treatment of schizophrenia is underlined [5].
In another study by Ginsberg et al., [24], in which patients
with schizophrenia were asked about their expectations
concerning the treatment, it became clear that besides the
alleviation of symptoms, patients required an improvement
on social functioning such as more daily activities, social
contacts and career opportunities. The improvement of
psychological and social performance also means successful
personal, social and professional reintegration [25,26].
The aim of this study was to estimate the correlation
between the PSP and Positive and Negative Syndrome
Scale (PANSS) (convergent validity) in a Greek sample of
patients with schizophrenia under heterogeneous thera-
peutic strategies in routine clinical practice.
Methods
Subjects
Two thousand and ten (2010) patients in outpatient setting
(1212 males, 783 females) diagnosed with schizophrenia
according to DSM–IV criteria were included. The relevant
data of participants were collected from the medical re-
cords kept by physicians (N = 160) who work in private
and in public facilities all over the country.
The majority of 1121 were diagnosed with paranoid-
hallucinatory schizophrenia. The other half could be
subtyped as undifferentiated (N = 266), residual (N = 256),
disorganized (N = 203) and catatonic type (N = 50). Pa-
tients’ mean age was 38.9 years, ranging from 18 to
84 years. The mean duration of the disease in the studied
population was estimated at 12 (SD 9.3) years, with a
10-year median and a maximum of 54 years. The aver-
age duration of treatment was estimated at 11 (SD 9.1)
years with a median of 9 years and a maximum of
53 years. (For further details see Table 1).
Measures
For the patients’ assessment, the included measures were
the Positive and Negative Syndrome Scale (PANSS) [27]
and the Personal and Social Performance Scale (PSP) [17].
The PSP measures four areas of social and individual per-
formance (socially useful activities; personal and social re-
lationships; self-care; disturbing and aggressive behaviors)
independently of symptomatology and provides a score
between 1 and 100, divided into 10 equal intervals to rate
the degree of difficulty. Higher scores represent better per-
sonal and social functioning, with ratings from 91–100 re-
ferring to more than adequate functioning, while scores
Table 1 Demographic and individual characteristics of
study population (n = 2010)1
Sex (n = 1995)2 n (%)
Male (%) 1212 (60.75)
Female (%) 783 (39.25)
Age Years
Mean age (years) [male/female] 38.9 [38.7/39.1]
Range age [male/female] 18-84 [18–84/18-81]
Status of relationship (n = 1960)2 n (%)
Single [male/female] 1297 (66.17) [851/446]
Married [male/female] 449 (22.9) [239/210]
Divorced [male/female] 188 (9.59) [86/102]
Other [male/female] 26 (1.32) [8/18]
Education (n = 1977)2 n (%)
<6 years education 218 (11.02)
6-9 years education 566 (28.63)
9-12 years education 697 (35.26)
>12 years of education 496 (25.09)
Occupation (n = 1793)2 n (%)
Unemployed 922 (51.42)
Part-time employed 380 (21.19)
Full-time employed 491 (27.39)










1total number of study population.
2valid answers.
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vision is needed.
The PANSS is a 30-item rating scale, specifically de-
veloped to assess patients with schizophrenia and is
divided in three subscales, a Positive Scale with seven
positive symptoms (P1-P7), a Negative Scale with
seven negative symptoms (N1-N7) and a General Psy-
chopathology Scale with 16 items (G1-G16). Sub-scale
scores were shown to be independent of each other.
For each of the 30 items there is a definition and seven
possible rating points, representing increasing levels
of psychopathology severity (1 = absent; 2 = minimal;
3 = mild; 4 = moderate; 5 = moderate-severe; 6 = severe;
7 = extreme). The PANSS is scored by summation ofratings across items, thus the potential ranges are 7–49
for the Positive and Negative Scales and 16–112 for the
General Psychopathology Scale.
Procedures
The study had a prospective longitudinal design. Measure-
ment was conducted in two consecutive visits within six
months. Clinical information regarding length of time since
initial diagnosis of schizophrenia according to DSM-IV
classification, duration and category of anti-psychotic treat-
ment and demographic and socioeconomic features were
obtained from written questionnaires supplied by the re-
search team and filled by the treating doctors; one for each
of the two visits for each patient. In addition, the treating
doctors rated the patients on PSP and PANSS in the first
and second visit. Assessment of symptom severity and type
of psychopathology was performed with the Greek version
of PANSS, as adapted for the Greek population by Lykouras
et al. [28]. Assessment of psychosocial functioning was per-
formed with the linguistic validated (forward translation,
backward translation for quality control, and pilot testing)
PSP scale. All participating physicians were trained and
instructed how to collect the required information, espe-
cially for the PSP scale. The observation period included
the time of patient’s entry in the study and collection of
data at baseline and a second visit after 6 months.
The study was approved by the Board of the Medical
School of Patras, the Research Committee of the University
of Patras and the National Organization for Medicines,
Greece. All participants were informed about the study and
provided written informed consent for participation.
Statistical analysis
All analyses were performed using SPSS version 17.0.
Demographic and clinical information were evaluated
using descriptive statistics. Due to non normality of the
data distribution, non parametric tests were used for the
correlations between the PSP and PANSS scales. PSP
scale score was compared with the total score and indi-
vidual scores of PANSS using the Spearman’s rho rank
correlation coefficient. A generalized linear model ana-
lysis was used to quantify the correlation between both
scales. The PSP’s ability to detect changes in clinical sta-
tus from baseline to endpoint of the study was evaluated
through regression analysis on the change in total score
of PANSS of the corresponding change in the PSP scale.
A 0.05 statistical significance level was used.
Results
Course of the clinical symptoms based on the PANSS and
PSP scales
The course of the disease according to PANSS scale,
within six months, showed significant improvement in
most parameters. Less than 10% of patients had serious
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ters. In particular, the percentage of patients who had delu-
sions decreased from 35.7% to 5.4% and patients with ideas
of persecution and distrust from 31.7% to 5.1%. In addition,
the percentage of patients with serious problems of anxiety
dropped from 27.1% to 4.5%.
According to the PSP scale, one in two patients
showed increased difficulties in more than one area, or
severe difficulties in one or all areas of personal and
social performance [<50 points, 52.6%] during the first
visit. Six months later the course of the disease im-
proved considerably as the proportion of patients with
increased difficulty reduced from 52.6% to 20.8% and
the proportion of patients with a good level of personal
and social performance [>60 points] increased from
29.3% in the first visit to 60.4% in the second visit.
Most patients are classified in a better level of perform-
ance (average improvement of about 1.5 that is 15 points)
(Table 2).
Table 2 also reflects the mean PANSS sum score and the
individual scores on the Positive and Negative Symptom
Scale and the General Psychopathology scale of PANSS, the
total mean score of PSP scale in the first and second visit
and their differences.
Item correlation of PANSS and PSP scale
Spearman’s rho correlations showed consistent relationships
between PANSS items in both assessments. They ranged for
the Positive – Negative Scales from 0.40 to 0.57 and for the
General Psychopathology scale from 0.67 to 0.73. The
correlations between categories in different estimates
were generally low to moderate but still very important.
The corresponding categories (Positive 1st visit –PositiveTable 2 Evaluation of clinical symptoms and their
severity according to PANSS and PSP scales in the 1st and
2nd visit
1st visit 2nd visit Difference
PANSS n = 1768 n = 1768 n = 1655
Total mean score (SD) 90.24 (27.8) 65.33 (21.5) −24.67 (27.3)
Minimum – maximum 32 – 196 30 – 142 [−127] – [64]
Median Value 86 61 −20
Positive Symptoms n = 1908 n = 1929 n = 1841
Mean score (SD) 22.14 (8.1) 15.15 (6) −6.89 (8.6)
Negative Symptoms n = 1924 n = 1951 n = 1886
Mean score (SD) 21.99 (9) 16.39 (6.9) −5.55 (8.5)
General Psychopathology
Symptoms
n = 1826 n = 1915 n = 1655
Mean score (SD) 46.11 (14.8) 33.91 (11.3) −12.11 (14.3)
PSP n = 1996 n = 1962 n = 1948
Total mean score (SD) 46.77 (17.38) 60.30 (13.89) 13.67 (19.15)
Minimum – maximum 5 – 90 15 – 90 [−60] – [75]2nd visit, Negative 1st visit – Negative 2nd visit, General
Psychopathology 1st visit – General Psychopathology 2nd
visit) showed, as expected, the highest correlations ranging
from 0.32 to 0.49. Also, General Psychopathology correla-
tions (0.27 – 0.38) were greater than those of the Positive
scale (0.19 – 0.30) and Negative scale (0.19 – 0.38). Finally,
the PANSS showed good reliability (intraclass correlation
coefficient ICC = 0.7958) (p < 0.001).
The correlations between the four categories of the
PSP scale were high in both assessments. In the fields of
socially useful activities, personal and social relationships
and self-care, it ranged from 0.56 to 0.77 in the initial
and from 0.60 to 0.76 in the final assessment. The field of
disturbing and aggressive behavior had lower but highly sig-
nificant correlations with the other fields which ranged
from 0.32 to 0.51 and were better in the initial assessment.
The identical categories showed (socially useful activities
1st – 2nd, personal and social relationships 1st – 2nd, self-
care 1st -2nd, disturbing and aggressive behavior 1st -2nd),
as expected, the higher correlations ranging from 0.25
to 0.35. Apart from this, the correlations of self-care
(0.21 – 0.22) were greater than the correlations of so-
cially useful activities (0.15 – 0.22), personal and social
relationships (0.10 – 0.19) and disturbing and aggressive
behavior (0.13 – 0.19) respectively. All correlations were
found to be statistically significant at p < 0.001 level.
Analysis of reliability and validity
Correlations between the PSP and PANSS scales
The correlation of the total score between the initial and
final PSP scale with the corresponding scores of the
PANSS total and individual scores are given in the Table 3.
The correlation of the final scores between the original
PSP and PANSS scale was negative, very high and very
significant in both visits (rho ≥ −0.50). All correlations
were statistically significant. Nevertheless, they were slightly
higher regarding the general psychopathology symptoms
mainly in comparison with the negative symptoms.
The correlation of the final score difference (Δ) between
the initial and final PSP and PANSS was −0.59 (p < 0.001)Table 3 Correlations of the PSP scale and PANSS total





PANSS initial score 1760 - 0.59
Positive scale 1st visit 1896 - 0.54
Negative scale 1st visit 1913 - 0.42
General psychopathology 1st visit 1818 - 0.55
PANSS final score 1844 - 0.50
Positive scale 2nd visit 1908 - 0.45
Negative scale 2nd visit 1930 - 0.41
General Psychopathology 2nd visit 1874 - 0.47
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scales the scores were improved, the differentiation of
the PANSS score showed greater variability (Spearman’s
rho −0.64) compared to the PSP (Spearman’s rho −0.73).
Parameters affecting the changes in the PSP scale
A further question might be whether the relationship be-
tween PSP and PANSS is quantifiable, i.e. to what extent
the change in one scale will be reflected in the other.
These findings were obtained using a generalized linear
model in which other variables that were studied have
also been taken into account (Table 4).
It appears that a unit decrease in the total score of the
PANSS scale corresponds to an increase of 0.42 points
of the scale of PSP (Table 4). Full time employees have
significantly better scores than the unemployed while a
change in family status causes a decrease of 8.6 points
on the score of the PSP (p < 0.05).
Discussion
The aim of this study was to estimate the correlation be-
tween the Personal and Social Performance (PSP) scale
and the Positive and Negative Syndrome Scale (PANSS)
(convergent validity) in a large Greek sample of chronic-
ally ill patients with schizophrenia under heterogeneous
therapeutic procedures in routine outpatient clinical
practice in two successive visits.
In previous studies, PSP has been used successfully on
patients with schizophrenia in the acute [18,19,29] and
stable stage [17,20,29] revealing high reliability and val-
idity. The present study supports the validity and reli-
ability of the PSP as a tool for assessing the social and
personal functioning in patients with schizophrenia in
routine outpatient clinical practice.
We estimated the correlation coefficients between the
PSP total score and PANSS total score and subscales inTable 4 Factors related to the changes in studied patients’
score of the PSP scale (General linear model analysis)






D_PANSSa - 0.42 <0.001 - 0.44 −0.39
Employment type
Full time employment 2.99 0.001 1.19 4.78
Part time employment 1.36 0.170 −0.58 3.30
Unemployed RC
Change of family status (co-habitation)
Yes −8.63 0.001 −13.94 −3.32
No RCb
aD_PANSS: changes in PANSS total score.
bRC: (Reference Category), R Squared = 0.380 (Adjusted R Squared = 0.378).2010 patients with schizophrenia and found as expected
negative, very high and very significant correlations be-
tween the two scales in both visits (rho ≤ −0.50).
It is obvious that the reassessment of the patients, six
months after the initial, showed a statistically significant
improvement in the PANSS scale and all its individual
components in total. Also, according to the PSP scale of
the reassessment most of the patients were classified in
a better level of performance. Although it was not our aim
to evaluate this finding, it is considered that the improve-
ment was partly due to the medication change. However,
the decrease in PANSS total score does not always mean
improvement in symptoms considered pathognomonic for
schizophrenia [30]. Indeed the largest difference noted in-
volved the general psychopathology scale.
In previous reports it has been argued that certain
PANSS items are more strongly correlated with the
PSP total score than other items [18,19]. Mainly nega-
tive symptoms are considered to better reflect social
dysfunction as the nature and chronicity of which,
seem to interfere in competent social interaction. In
this study, contrariwise, the correlations regarding the
general psychopathology symptoms were slightly higher,
mainly in comparison to the negative symptoms. As it
was shown in a meta-analysis of Eack and Newhill [31],
general psychopathology was more profoundly corre-
lated with assessments measuring quality of life in pa-
tients with schizophrenia than with either positive or
negative symptoms, indicating that chronic disability
and domains of general psychopathology scale such as
anxiety, lack of judgment and sensitivity, abnormal
thoughts and conscious social isolation, may be im-
portant factors influencing the level of adequate social
performance. Better psychosocial functioning is associated
with better quality of life [32]. Symptomatology though
alters as the disease progresses, resulting in different
patterns of association between symptoms and quality
of life [33] and it is plausible also for social functioning.
The PSP subscales scores were highly correlated with
each other in three out of four areas, both in the first
and second visit. Burns and Patrick [5] argue in the
ability of PSP to reflect the various phases of schizo-
phrenia with the domain of disturbing and aggressive
behavior concerning mainly patients in the acute stage
of the disease. Our results concerning patients with a
mean duration of the disease of 12 (SD = 9.3) years and
few patients in the acute stage of the disease fairly
agree with this remark since the correlations of the in-
dividual scores of PSP were slightly lower for the cat-
egory disturbing and aggressive behavior.
PSP is found to improve accordingly along with the
PANSS total score [34] and to be sensitive to clinical
change as this is given by correlations found statisti-
cally significant between change in the PSP and change
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final scores in our study reached a rho of −0.59 (p < 0.01),
a finding consistent with others in the literature [18,20].
Although an improvement in the scores was observed in
both scales, the differentiation of the PANSS score showed
greater variability (Spearman’s rho −0.64) compared to
the PSP (Spearman’s rho −0.73). This may partly be
due to the fact that PSP does not incorporate psycho-
pathological aspects [17].
A unit decrease in the total score of the PANSS scale
corresponded to an increase of 0.42 points on the scale
of PSP. Furthermore, full time employees have as expected
significantly better scores than the unemployed while a
change in family situation (divorced, widowed) causes a
decrease of 8.6 points on the score of the PSP.
The ratio of change (2.38) in the PANSS and the PSP
scale in our study is very close to the ratio of 2.19 found
in other similar studies [21-23]. In our study employment
type and change in the family/living situation exhibited
significant relations that were not totally reflected in
the scales. Apiquan et al., [29] have shown that patients
with low social functioning display demographic features
which are associated with poor prognosis such as un-
employment while a change in the family status often in-
dicates a decline in social performance as this appears as a
loss of the ability of living independently.
This study is limited in that correlation analyses were
performed only with the PANSS. Another limitation was
that we restricted our analysis to the positive, negative
and general psychopathology scales of PANSS not in-
corporating the five-factor (Negative, Positive, Excited/
Activation, Anxious-Depressed/Dysphoric, and Cognitive/
Disorganized/Autistic preoccupation) structure of the
PANSS [35,36]. Moreover, it would be desirable to assess a
correlation analysis of the PSP individual subdimensions
to PANSS subscores with respect to therapeutic proce-
dures used since alteration in medications could result in
extensive differences on social functioning [10,16]. For ex-
ample, Hough et al. [37] showed that paliperidone had an
effect on social functioning (assessed with PSP) over and
above its effect on symptoms (assessed with PANSS).
Conclusions
In conclusion, our results demonstrate that the PSP scale
is a reliable and valid tool for assessing the social and per-
sonal performance in patients with schizophrenia. The
strong negative correlation with PANSS indicates that this
short and useful tool for outpatient practice is sensitive to
the clinical changes observed and it can easily accompany
scales measuring psychopathology, in order to also evalu-
ate the level of social and personal functioning.
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